Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose study of LY3045697 in healthy volunteers
NL-OMON38917Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of LY3045697 in chronic kidney disease (CKD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Safety and tolerability of LY3045697. Started Jan 2013; status: active, not recruiting.
02
Drugs
LY3045697
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON38917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38917.